EGFR and non-small cell lung carcinoma: In the FLAURA trial, the progression-free survival (PFS) was only 10.2 months in patients with EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC who received standard EGFR-TKI as first-line treatment (8).